InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Unveils Study Data Showing 97% of Vivos Patients Report Reaching Desired Outcome
July 7, 2021

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Unveils Study Data Showing 97% of Vivos Patients Report Reaching Desired Outcome

Vivos Therapeutics (NASDAQ: VVOS) has released data from an independent patient survey related to its proprietary Vivos treatment for dental tissue anomalies and dentofacial malformations associated with obstructive sleep apnea (“OSA”) and other debilitating health conditions. The study reported that approximately 97% of patients surveyed said that they had achieved their desired outcome from the Vivos treatment for their OSA. Other study results show that 63% of patients reported that they depend on their dentist’s advice as they look for lasting solutions that addresses the root cause of their OSA and 29% indicated they searched for nonsurgical alternatives to current standards of care for treating OSA. Vivos is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate OSA. “Patients are the ultimate arbiter of whether a particular treatment modality has achieved its desired results,” said Vivos chair and CEO Kirk Huntsman in the press release. “This survey reaffirms that patients are in dire need of a solution for their OSA — one that is nonsurgical, noninvasive, nonpharmaceutical and low-cost — and that’s exactly the market niche that the Vivos treatment fills. The fact that nearly all patients surveyed reported that they had achieved their desired treatment outcome is a powerful testimony about their clinical and cosmetic results. Our technology just works.”

To view the full press release, visit https://ibn.fm/3z6jN 

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves a customized oral appliance and protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in more than 17,000 patients worldwide by more than 1,200 dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentist training and other value-added services in connection with using the Vivos System. For more information about this company, visit www.VivosLife.com.  

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).